Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Berlin - Delayed Quote • EUR Ionis Pharmaceuticals Inc (ISI.BE) Follow Compare 30.93 +0.70 +(2.32%) At close: February 21 at 8:08:17 AM GMT+1 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Ionis Pharmaceuticals price target lowered to $60 from $61 at Raymond James Raymond James lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $60 from $61 and keeps a Strong Buy rating on the shares. Ionis beat nicely in Q4, and the 2025 floor guidance for revenue and operating loss appears reasonable as Ionis transitions to more of a commercial story, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks Why Ionis Pharmaceuticals (IONS) Is Among the Most Oversold Healthcare Stocks to Buy Now We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) stands against other most oversold healthcare stocks to buy now. Are Healthcare Costs Rising in the US? Healthcare costs and spending have been rising […] Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus IONS reports better-than-expected top and bottom-line numbers for the fourth quarter. New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control CARLSBAD, Calif., February 20, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will present additional data from the pivotal Phase 3 OASIS and OASISplus studies, as well as three year data from the Phase 2 open-label extension (OLE) study of donidalorsen, the company’s investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE). Results will be presented at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organizati Ionis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations Ionis Pharmaceuticals ( NASDAQ:IONS ) Full Year 2024 Results Key Financial Results Revenue: US$705.0m (down 11% from FY... Q4 2024 Ionis Pharmaceuticals Inc Earnings Call Q4 2024 Ionis Pharmaceuticals Inc Earnings Call Ionis Pharmaceuticals Inc (IONS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... Ionis Pharmaceuticals Inc (IONS) reports a robust Q4 with significant revenue growth, strategic product launches, and a promising pipeline for future expansion. Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales On Wednesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) reported a fourth-quarter EPS loss of $0.66, up from a loss of $0.06, beating the consensus of a $1.10 loss. The company reported an adjusted net loss of $68 million versus a net income of $17 million. Ionis reported quarterly sales of $227 million, down from $325 million a year ago, beating the consensus of $137.6 million. Ionis says 2024 revenue of $705 million exceeded guidance as the company continued to generate revenue from diverse sour Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 41.07% and 65.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock? Ionis Pharmaceuticals: Q4 Earnings Snapshot CARLSBAD, Calif. AP) — Ionis Pharmaceuticals Inc. IONS) on Wednesday reported a loss of $104 million in its fourth quarter. Ionis reports fourth quarter and full year 2024 financial results CARLSBAD, Calif., February 19, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the fourth quarter and full year ended December 31, 2024. Ionis Pharmaceuticals (IONS): Among Top Insider Stock Buys And Sells In January We recently published a list of 10 Top Insider Stock Buys And Sells In January. In this article, we are going to take a look at where Ionis Pharmaceuticals (NASDAQ:IONS) stands against other top insider stock buys and sells in January. Ever heard of the “January effect?” In case you haven’t, a “January effect” is […] Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy? Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Why Insiders Are Selling Ionis Pharmaceuticals, Inc. (IONS) Recently We recently compiled a list of the 10 Mid-Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) stands against the other feminist stocks. We previously covered 10 Mid-Cap Stocks Insiders Are Buying Recently. Why should investors analyze insider trading activity? Insiders, or people […] Why Ionis Pharmaceuticals, Inc. (IONS) Is Among the Best Healthcare Stocks To Buy According to Analysts We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry witnessed significant financial pressure. This is evidenced by the fact that […] Ionis to hold fourth quarter and full year 2024 financial results webcast CARLSBAD, Calif., February 05, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 19th at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2024 financial results. FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMACAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and the European Medicines Agency (EMA) has validated the application for a higher dose regimen of nusinersen for spina Why Ionis Pharmaceuticals (IONS) Is the Biotech Stock with Biggest Upside Potential We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to take a look at where Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) stands against other biotech stocks with the biggest upside potential. Improving Trends for Biotech Stocks While 2024 was a “challenging” year for biotech stocks, […] Performance Overview Trailing total returns as of 2/21/2025, which may include dividends or other distributions. Benchmark is S&P 500 Return ISI.BE S&P 500 YTD -9.08% +2.24% 1-Year -24.27% +20.70% 3-Year +8.56% +38.27%